ClinicalTrials.gg
CompletedNCT01327599Updated Feb 10, 2014Results posted

Efficacy of Changing to DUOTRAV® From Prior Therapy

A Phase 4 interventional study of Travoprost 0.004%+Timolol 0.5% ophthalmic solution in Open-Angle Glaucoma, Ocular Hypertension and Pigment Dispersion Glaucoma, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-10.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
33rd of 45
60 · median 135
Started
2011
with 8 others
Phase 4
22 of 46
2 open now
Registered
27th of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 33rd largest by enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2011, is one of 22 in phase 4, and was the 27th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of this study was to assess the efficacy and tolerability of changing to DUOTRAV® from prior bimatoprost 0.03%/timolol 0.5% pharmacotherapy in subjects with open-angle glaucoma or ocular hypertension having uncontrolled intraocular pressure (IOP).

03

Conditions studied

  • Open-Angle Glaucoma
  • Ocular Hypertension
  • Pigment Dispersion Glaucoma

Keywords

  • Open-angle glaucoma
  • Ocular hypertension
  • Pigment dispersion glaucoma
  • Intraocular pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of ocular hypertension, open-angle or pigment dispersion glaucoma in at least one eye.
  • Stable IOP-lowering regimen of bimatoprost 0.03%/timolol 0.5% therapy (either administered concomitantly or in a fixed combination) within 4 weeks prior to the screening visit.
  • IOP considered to be safe (in the opinion of the investigator), in both eyes, to assure clinical stability of vision and the optic nerve throughout the study period.
  • IOP between 19 to 35 mmHg (at any time of the day) in at least one eye (which would be designated as the study eye).
  • Willing to discontinue the use of all other ocular hypotensive medication(s) prior to receiving the study medication for the entire course of the study.
  • Able to follow instructions and willing and able to attend all study visits.
  • Best corrected visual acuity of 6/60 (20/200 Snellen, 1.0 LogMAR) or better in each eye.
  • Sign .
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Known medical history of allergy, or poor tolerance to any component of DuoTrav® that is deemed in the opinion of the Principal Investigator.
  • Corneal dystrophies in either eye.
  • Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.
  • Bronchial asthma or a history of bronchial asthma, bronchial hyper reactivity, or severe that would preclude the safe administration of a topical beta-blocker.
  • History of severe allergic rhinitis.
  • A condition, which in the opinion of the Principal Investigator, would interfere with optimal participation in the study, or which would present a special risk to the subject.
  • Participation in any other study within 30 days prior to the Screening Visit.
  • Other protocol-defined exclusion criteria may apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    DUOTRAV®

    Travoprost 0.004%+Timolol 0.5% ophthalmic solution, 1 drop to the study eye(s) once a day at 8:00 PM for 12 weeks

    Drug: Travoprost 0.004%+Timolol 0.5% ophthalmic solution

Interventions

  • DrugTravoprost 0.004%+Timolol 0.5% ophthalmic solution

    Drug page: Travoprost

    Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)

    Also known as: DUOTRAV®

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in IOP at Week 12 in Subjects Using Ganfort® at Baseline

    IOP (fluid pressure in the eye) was measured with Goldmann applanation tonometry. A positive number change from baseline indicates an increase in intraocular pressure, which may be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye was chosen as the study eye, and only the study eye was used for analysis.

    Time frame: Week 12

Secondary outcomes

  1. Mean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Week 12 in Subjects Using Ganfort® at Baseline

    The OSDI is a 12-item quality of life questionnaire designed to assess ocular surface symptoms, their severity, and their impact on the subject's ability to function. Each item was scored by the subject on a 0-4 Likert-type scale (0=None, 4=All of the Time), with a resultant overall score of 0-100 (0=no disability, 100=complete disability). A negative number change from baseline represents a perceived improvement in ocular health.

    Time frame: Week 12

  2. Mean Change From Baseline in Ocular Hyperemia Score at Week 12 in Subjects Using Ganfort® at Baseline

    Ocular hyperemia (visible eye redness) was assessed during slit lamp examination and graded on a 5-point scale (0=none, 4=severe). A positive number change from baseline indicates an increase in ocular redness. One eye was chosen as the study eye, and only the study eye was used for analysis.

    Time frame: Week 12

  3. Percentage of Subjects Who Reach Target IOP of ≤ 18 mmHg in Subjects Using Ganfort® at Baseline

    IOP (fluid pressure in the eye) was measured with Goldmann applanation tonometry. An increase in intraocular pressure may be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye was chosen as the study eye, and only the study eye was used for analysis.

    Time frame: Week 4, Week 12

  4. Mean Change From Baseline in IOP at Week 4 in Subjects Using Ganfort® at Baseline

    IOP (fluid pressure in the eye) was measured with Goldmann applanation tonometry. A positive number change from baseline indicates an increase in intraocular pressure, which may be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye was chosen as the study eye, and only the study eye was used for analysis.

    Time frame: Week 4

07

Results

Posted Jan 10, 2014

Participant flow

Participants were recruited from 10 study centers in France and 3 study centers in Germany.

Participant flow — Overall Study
MilestoneDUOTRAV®
Started60
Completed57
Not completed3
Withdrew: Adverse event1
Withdrew: Could not attend visit1
Withdrew: Withdrawal of consent1

Outcome measures

PrimaryMean Change From Baseline in IOP at Week 12 in Subjects Using Ganfort® at Baseline

IOP (fluid pressure in the eye) was measured with Goldmann applanation tonometry. A positive number change from baseline indicates an increase in intraocular pressure, which may be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye was chosen as the study eye, and only the study eye was used for analysis.

Time frame:
Week 12
Reported as:
Mean · millimeters mercury (mmHg)
Mean Change From Baseline in IOP at Week 12 in Subjects Using Ganfort® at Baseline
millimeters mercury (mmHg)DUOTRAV®
Baseline (Day 1)20.0 ± 1.0
Change from baseline at Week 12-3.8 ± 1.9
SecondaryMean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Week 12 in Subjects Using Ganfort® at Baseline

The OSDI is a 12-item quality of life questionnaire designed to assess ocular surface symptoms, their severity, and their impact on the subject's ability to function. Each item was scored by the subject on a 0-4 Likert-type scale (0=None, 4=All of the Time), with a resultant overall score of 0-100 (0=no disability, 100=complete disability). A negative number change from baseline represents a perceived improvement in ocular health.

Time frame:
Week 12
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Ocular Surface Disease Index (OSDI) Score at Week 12 in Subjects Using Ganfort® at Baseline
Units on a scaleDUOTRAV®
Baseline (Day 1)14.9 ± 10.9
Change from Baseline at Week 12-3.6 ± 6.5
SecondaryMean Change From Baseline in Ocular Hyperemia Score at Week 12 in Subjects Using Ganfort® at Baseline

Ocular hyperemia (visible eye redness) was assessed during slit lamp examination and graded on a 5-point scale (0=none, 4=severe). A positive number change from baseline indicates an increase in ocular redness. One eye was chosen as the study eye, and only the study eye was used for analysis.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline in Ocular Hyperemia Score at Week 12 in Subjects Using Ganfort® at Baseline
units on a scaleDUOTRAV®
Mean Change From Baseline in Ocular Hyperemia Score at Week 12 in Subjects Using Ganfort® at Baseline-0.1 ± 0.7
SecondaryPercentage of Subjects Who Reach Target IOP of ≤ 18 mmHg in Subjects Using Ganfort® at Baseline

IOP (fluid pressure in the eye) was measured with Goldmann applanation tonometry. An increase in intraocular pressure may be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye was chosen as the study eye, and only the study eye was used for analysis.

Time frame:
Week 4, Week 12
Reported as:
Number · percentage of participants
Percentage of Subjects Who Reach Target IOP of ≤ 18 mmHg in Subjects Using Ganfort® at Baseline
percentage of participantsDUOTRAV®
Week 478.6
Week 1285.5
SecondaryMean Change From Baseline in IOP at Week 4 in Subjects Using Ganfort® at Baseline

IOP (fluid pressure in the eye) was measured with Goldmann applanation tonometry. A positive number change from baseline indicates an increase in intraocular pressure, which may be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye was chosen as the study eye, and only the study eye was used for analysis.

Time frame:
Week 4
Reported as:
Mean · millimeters mercury (mmHg)
Mean Change From Baseline in IOP at Week 4 in Subjects Using Ganfort® at Baseline
millimeters mercury (mmHg)DUOTRAV®
Baseline (Day 1)20.1 ± 1.1
Change from Baseline at Week 4-3.8 ± 2.1

Adverse events

Collected over Adverse events were collected for the duration of the study (1 year, 3 months). An adverse event was defined as any untoward medical occurrence in a subject administered a study treatment regardless of causal relationship.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DUOTRAV®—0/60 (0%)0/60 (0%)

Baseline characteristics

This reporting group includes all participants who received study medication and had at least one on-therapy study visit (Intent-to-treat).

Age, Continuous
Age, Continuous(years)DUOTRAV®
Mean73.2 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)DUOTRAV®
Female38
Male21
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2011
First posted
Apr 1, 2011
Start
Aug 2011
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Jan 10, 2014
Last update
Feb 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01327599
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Apr 1, 2011
Start date
Aug 2011
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Jan 10, 2014
Last update
Feb 10, 2014

Study contacts

Severine Durier, Pharm.D
study director · Alcon Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion